Loading…
Jaguar Health, Inc. is projected to decline to $2.17 by 2027, a -6% move from its current price of $2.31. JAGX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.19 | $2.31 | $2.44 | +0.10% |
| Jul 14 | $2.14 | $2.31 | $2.50 | +0.20% |
| Jul 15 | $2.11 | $2.32 | $2.54 | +0.30% |
| Jul 16 | $2.08 | $2.32 | $2.58 | +0.40% |
| Jul 17 | $2.06 | $2.32 | $2.62 | +0.50% |
| Jul 18 | $2.04 | $2.32 | $2.65 | +0.60% |
| Jul 19 | $2.02 | $2.33 | $2.68 | +0.70% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.02 | $2.33 | $2.68 | +0.70% |
| Week 2 | $1.91 | $2.34 | $2.87 | +1.40% |
| Week 3 | $1.84 | $2.36 | $3.02 | +2.11% |
| Week 4 | $1.78 | $2.38 | $3.16 | +2.83% |
| Week 5 | $1.74 | $2.39 | $3.29 | +3.55% |
| Week 6 | $1.70 | $2.41 | $3.42 | +4.27% |
| Week 7 | $1.66 | $2.43 | $3.54 | +5.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focusing on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.
Headquartered in San Francisco, California, the company concentrates on prescription and non-prescription products for companion and production animals, and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
In addition, the company is developing Mytesi, which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea.
Jaguar Health, Inc. is listed with a current price of $2.41 and a market capitalization of $11.71M, with a rank of 5079. The near-term outlook and price dynamics are reflected in the 2026 forecast, which shows a min of $2.25, an avg of $2.41, and a max of $3.73 with a 0% ROI, indicating little expected movement from the current level.
This places the stock in a subdued near-term trajectory despite the low market cap.
A major floor 39.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.6% away) — a key level to hold.
The nearest ceiling, 53.7% above — a clean break opens room to run.
A major ceiling 892.4% above — clearing it would confirm fresh momentum.
Key JAGX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JAGX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.51 | Sell | $2.48 | Sell |
| MA 10 | $2.74 | Sell | $2.60 | Sell |
| MA 20 | $2.64 | Sell | $2.78 | Sell |
| MA 50 | $3.22 | Sell | $4.89 | Sell |
| MA 100 | $10.20 | Sell | $13.26 | Sell |
| MA 200 | $29.62 | Sell | $394.83 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.40 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -104.77 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | -9.77 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.67 | Sell |
| Awesome (5,34) | -0.31 | Sell |
| Ultimate (7,14,28) | 22.52 | Buy |
| Momentum (10) | -0.42 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 2.27 | Buy |
| ADX (14) | 31.52 | Sell |
| ATR (14) | 0.16 | Info |
The 30-day technical picture is NEUTRAL. The RSI14 is 30, suggesting possible near-term oversold momentum. The stock’s short-term moving averages show SMA50 at $3.49 and SMA200 at $30.27, highlighting a wide gap between shorter-term and longer-term trends.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.25 | $2.31 | $3.56 | 0% | Neutral | |
| $1.57 | $2.17 | $3.23 | -6% | Neutral | |
| $1.29 | $1.89 | $3.00 | -18% | Bearish | |
| $1.36 | $2.10 | $3.50 | -9% | Neutral | |
| $1.17 | $1.89 | $3.28 | -18% | Bearish | |
| $1.42 | $2.39 | $4.30 | +4% | Neutral | |
| $1.67 | $2.94 | $5.44 | +27% | Bullish | |
| $1.54 | $2.83 | $5.38 | +22% | Bullish | |
| $1.57 | $3.00 | $5.86 | +30% | Bullish | |
| $1.36 | $2.70 | $5.40 | +17% | Neutral | |
| $1.78 | $3.96 | $8.69 | +71% | Bullish | |
| $2.70 | $6.00 | $13.80 | +160% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.25 | $2.31 | $2.81 | +0.00% |
| August 2026 | $2.02 | $2.45 | $3.09 | +6.06% |
| September 2026 | $2.06 | $2.53 | $3.26 | +3.25% |
| October 2026 | $1.98 | $2.46 | $3.23 | -2.58% |
| November 2026 | $2.01 | $2.52 | $3.35 | +2.28% |
| December 2026 | $2.08 | $2.64 | $3.56 | +4.73% |
Click any year to see its month-by-month JAGX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, JAGX is projected to trade between $2.25 and $3.56, averaging $2.31 — a potential gain of 0% from today's $2.31. A consolidation phase looks the most probable path here.
Jaguar Health, Inc.'s 2027 outlook centres on $2.17, within a $1.57 to $3.23 range. That is -6% versus the projected 2026 average. That marks a -6% change versus current levels. Price action looks broadly range-bound.
By 2028, JAGX could reach as high as $3.00, with a base case around $1.89 and support toward $1.29 — roughly -18% from $2.31. Expect choppier, lower action through this leg of the cycle.
Expect JAGX to range from $1.36 to $3.50 through 2029. The $2.10 average target implies a -9% move from current prices. That is up +11% on the projected 2028 average. Price action looks broadly range-bound.
The JAGX price prediction for 2030 points to an average of $1.89 (low $1.17, high $3.28) — a potential decline of -18% on today's $2.31. Expect choppier, lower action through this leg of the cycle.
In 2031, JAGX is projected to trade between $1.42 and $4.30, averaging $2.39 — a potential gain of +4% from today's $2.31. That is up +27% on the projected 2030 average. Price action looks broadly range-bound.
Jaguar Health, Inc.'s 2032 outlook centres on $2.94, within a $1.67 to $5.44 range. That is up +23% on the projected 2031 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, JAGX could reach as high as $5.38, with a base case around $2.83 and support toward $1.54 — roughly +22% from $2.31. Momentum favours further upside here.
Expect JAGX to range from $1.57 to $5.86 through 2034. The $3.00 average target implies a +30% move from current prices. That is up +6% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The JAGX price prediction for 2035 points to an average of $2.70 (low $1.36, high $5.40) — a potential gain of +17% on today's $2.31. Price action looks broadly range-bound.
In 2040, JAGX is projected to trade between $1.78 and $8.69, averaging $3.96 — a potential gain of +71% from today's $2.31. That is up +46% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Jaguar Health, Inc.'s 2050 outlook centres on $6.00, within a $2.70 to $13.80 range. That is up +51% on the projected 2040 average. That marks a +160% change versus current levels. Momentum favours further upside here.
Investing $1,000 in JAGX today (≈ 432.900433 JAGX) could be worth
$2,596.47
+$1,596.47 (+160%) by 2050 · US Dollar
Based on the average projected JAGX price of $6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JAGXwould be worth at today's price.
$1,000 invested in JAGX on Jul 10, 2025 (≈ 10.863661 JAGX) would be worth
$25.1
-$974.9 (-97.5%) today · 0.03× · US Dollar
Based on a JAGX entry price of $92.05 vs. today's $2.31.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.81 | $822.06 | -17.8% |
| 1 month ago | $2.75 | $840 | -16.0% |
| 3 months ago | $12.91 | $178.86 | -82.1% |
| 6 months ago | $29.05 | $79.52 | -92.0% |
| 1 year ago | $92.05 | $25.1 | -97.5% |
| All time (5.0y) ago | $17,600,624 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JAGX forecast.
Our base-case forecast reaches $4.60 around 2050.
Implied market cap at $4.60: $22.34M
The multi-year forecast shows a mixed path with near-term softness followed by a more pronounced later-cycle upturn. For 2026, the avg price is $2.41 with a 0% ROI. The sequence through 2029-2035 includes declines to a 2030 avg of $1.93 (ROI -20) before a rebound, with 2032 avg $3.08 (ROI 27.9) and 2034 avg $3.14 (ROI 30.5).
The horizon improves notably in 2040, with an avg of $4.16 and ROI 72.6, and again in 2050, with an avg of $6.21 and ROI 157.8. These results imply substantial long-term upside but also meaningful volatility and downside risk along the way, reflecting that estimates are not guarantees. Investors should consider the wide range of possible outcomes, particularly the bear-case paths shown in the 2027-2030 window before the later bullish years.
Tap a question to reveal the answer.
The 2030 forecast lists an avg price of $1.93 with a min of $1.19 and a max of $3.35, and ROI of -20%. The sentiment is BEARISH.
Near term shows mixed signals (2026 avg $2.41, ROI 0; 2027 avg $2.23, ROI -7.3; 2028 avg $1.95, ROI -19). Long term points to potential upside (2040 avg $4.16, ROI 72.6; 2050 avg $6.21, ROI 157.8), but these are estimates and not guarantees.
Yes in the forecast’s upside paths: 2032 max $5.71, 2033 max $5.58, 2034 max $6.14, and even higher in later years (e.g., 2040 max $9.13, 2050 max $14.29). These are not guaranteed outcomes.
Current price is $2.41 and market cap is $11.71M.
The 30-day range is from $1.65 to $3.52, with support at $2.25 and resistance at $3.55. The RSI is 30, indicating neutral momentum.
Jaguar Health, Inc. Community Discussion
0Share your Jaguar Health, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.